VP
ACHV icon

venBio Partners’s Achieve Life Sciences ACHV Stock Holding History

venBio Partners’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.6M Buy
+5,914,720
New +$28.2M 7.44% 4

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM

venBio Partners's ACHV Position: Q2 2026 in Review

venBio Partners opened a new position in Achieve Life Sciences (ACHV) in Q2 2026: 5,914,720 shares worth $38.6M. The stake represents 7.44% of the portfolio and ranks #4 among its holdings.

102 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • venBio Partners held 5,914,720 shares of Achieve Life Sciences worth $38.6M as of Q2 2026.
  • Achieve Life Sciences was a new venBio Partners position in Q2 2026.
  • Achieve Life Sciences made up 7.44% of venBio Partners's portfolio in Q2 2026, its #4 holding.
  • 102 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on venBio Partners's 13F filing for Q2 2026, filed 14 Aug 2026.